We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
An outline concerning the potential use of recombinant human thyrotropin for improving radioiodine therapy of multinodular goiter.
- Authors
Geraldo Medeiros-Neto; Suemi Marui; Meyer Knobel
- Abstract
Abstract Radioiodine (131I) treatment for nontoxic and toxic multinodular goiter (MNG) is an alternative therapeutic procedure used especially for patients with contraindication for surgery. Several studies have been conducted in recent years assessing the use of recombinant human TSH (rhTSH) in increasing 131I uptake in MNGs. This procedure also decreases the activity level of the administered 131I, changes the distribution of 131I in the thyroid, lowers the absorption dose, and dramatically reduces the volume of the goiter (50–75% of the baseline volume). A major disadvantage, however, is the induction of hypothyroidism in a relatively large number of patients. A transient increase in thyroid volume and tenderness was noted in the first week of treatment. Also a short period (2–4 weeks) of hyperthyroidism was observed in most patients with potential consequences particularly for the elderly. Still, there has been no evidence to date that the adverse effects outweigh the positive results of using rhTSH. The use of rhTSH in benign goiter disease has not yet been approved worldwide, but its positive activity in MNG is remarkable and promising.
- Subjects
IODINE isotopes; GOITER; THYROTROPIN; RECOMBINANT proteins; HYPERTHYROIDISM
- Publication
Endocrine (1355008X), 2008, Vol 33, Issue 2, p109
- ISSN
1355-008X
- Publication type
Article
- DOI
10.1007/s12020-008-9077-7